Screening of BRCA1 and BRCA2 genes and their therapeutic implications in triple-negative breast cancer: a systematic review of the literature
Conteúdo do artigo principal
Resumo
O câncer de mama representa uma das neoplasias de maior prevalência e mortalidade entre as mulheres, exigindo intervenções estratégicas de saúde pública para mitigar seus impactos sociais e clínicos. Este trabalho tem como objetivo analisar os aspectos biológicos e epidemiológicos do câncer de mama no Brasil, destacando os mecanismos celulares envolvidos na progressão tumoral e a relevância do rastreamento precoce. Metodologia: Trata-se de uma revisão narrativa da literatura focada na regulação do ciclo celular, nas alterações da fase de síntese (fase S) e nas disparidades regionais de acesso ao diagnóstico no cenário brasileiro.Conduzida de acordo com as diretrizes PRISMA 2020 (Preferred Reporting Items for Systematic Reviews and Meta-Analyses), as busca para esta revisão foi realizada na base de dados PubMed, resultando na seleção de 17 artigos para análise. Resultados: A literatura aponta que a progressão tumoral está intimamente associada a falhas nos pontos de checagem da replicação celular, favorecendo a proliferação desordenada de células atípicas. Sob a ótica epidemiológica, constatam-se marcantes desigualdades regionais na incidência e na mortalidade pela doença, influenciadas por fatores socioeconômicos e barreiras no acesso aos serviços de saúde. Contudo, a implantação de programas de rastreamento sistemático demonstra alta eficácia na detecção de lesões em estágios subclínicos, aumentando expressivamente as taxas de cura e permitindo abordagens terapêuticas menos invasivas. Conclusão: A compreensão integrada dos mecanismos moleculares do ciclo celular aliada a estratégias regionais assertivas de rastreamento é fundamental para reduzir a mortalidade, otimizar recursos em saúde pública e melhorar o prognóstico e a qualidade de vida das pacientes.
Detalhes do artigo

Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Declaração de Direito Autoral - Proposta de Política para Periódicos de Acesso Livre
Autores que publicam na Revista Brasileira de Ciências Biomédicas (RBCBM) concordam com os seguintes termos:
1 - Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Creative Commons Attribution License que permitindo o compartilhamento do trabalho com reconhecimento da autoria do trabalho e publicação inicial nesta revista.
2 - Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
3 - Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado.
Este é um artigo de acesso aberto sob a licença CC- BY
Referências
Zhang Y, et al. Healthy lifestyles, systemic inflammation and breast cancer risk: a mediation analysis. BMC Cancer. 2024;24(1).
Instituto Nacional de Câncer (INCA). Estimativa 2022: Incidência de Câncer no Brasil [2022 Estimate: Cancer Incidence in Brazil]. Rio de Janeiro: INCA; 2022.
Santos MO, et al. Estimativa de incidência de câncer no Brasil, 2023–2025 [Estimated cancer incidence in Brazil, 2023–2025]. Rev Bras Cancerol. 2023;69(1).
Mercadante AA, Kasi A. Genetics, cancer cell cycle phases. [S.l.]: StatPearls Publishing; 2023. Updated 2023 Aug 14. Available from: https://www.ncbi.nlm.nih.gov/books/NBK585118/. Accessed 2025 Sep 5.
Alberts B, Johnson A, Lewis J, et al. An overview of the cell cycle. In: Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 4th ed. New York: Garland Science; 2002.
Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Ann Oncol. 2015;26(7):1291–1299.
Wong EV. Tumor Suppressor Genes. In: Cells: Molecules and Mechanisms. LibreTexts Publishing; 2020. Available from: https://bio.libretexts.org/Bookshelves/Cell_and_Molecular_Biology/Cells__Molecules_and_Mechanisms_(Wong)/16%3A_Viruses_Cancer_and_the_Immune_System/16.05%3A_Tumor_Suppressor_Genes.
Shimelis H, LaDuca H, Hu C, Hart SN, Na J, Thomas A, et al. Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing. J Natl Cancer Inst. 2018;110(8):855–862.
Wang DY, Gendoo DMA, Ben-David Y, Woodgett JR, Zacksenhaus E. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling. Breast Cancer Res. 2019;21(1):18.
Gene [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004– [cited 2026 Apr 14]. Available from: https://www.ncbi.nlm.nih.gov/gene/
Lips EH, et al. Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. Breast Cancer Res Treat. 2013;140(1):63–71.
Lehmann BD, et al. Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. Nat Commun. 2021;12(1):6276.
Gupta A, et al. A non-invasive method for concurrent detection of early-stage women-specific cancers. Sci Rep. 2022;12(1):19149.
Ugioni L, et al. Impact of mammography screening on the treatment of women diagnosed with breast cancer. Mastology. 2020;30:e20200020.
Cadavid-Fernández N, et al. The role of core needle biopsy in diagnostic breast pathology. Rev Senol Patol Mamaria. 2022;35(4):155–162.
Sinha I, et al. Potential early markers for breast cancer: a proteomic approach comparing saliva and serum samples in a pilot study. Int J Mol Sci. 2023;24(4):3849.
Ye F, et al. Insights into the impacts of BRCA mutations on clinicopathology and management of early-onset triple-negative breast cancer. Front Oncol. 2021;10:590113.
Cantor SB. Revisiting the BRCA-pathway through the lens of replication gap suppression: “Gaps determine therapy response in BRCA mutant cancer.” DNA Repair (Amst). 2021;107:103199.
Sadeghi F, et al. Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: review of radiosensitivity assays. Biol Proced Online. 2020;22(1):13.
Brianese RC, et al. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation. Breast Cancer Res Treat. 2018;167(3):803–814.
Richters L, et al. Genetic alterations, therapy response, and survival among patients with triple-negative breast cancer: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2025;8(2):e2461639.
Li RQ, et al. Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer. Sci Rep. 2024;14(1).
Telli ML, et al. Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status. Breast Cancer. 2024;31(5):886–897.
Mutai R, et al. The impact of germline BRCA pathogenic variants in locally advanced, triple-negative breast cancer treated with platinum-based neoadjuvant chemotherapy. Breast Cancer Res Treat. 2024;205(2):241–248.
Moreno M, et al. Risk of metastasis in BRCA2 carriers diagnosed with triple-negative breast cancer. Cancer Med. 2023;12(15):16129–16141.
Samusieva A, et al. Contribution of BRCA1 5382insC mutation to triple-negative and luminal types of breast cancer in Ukraine. Breast Cancer Res Treat. 2022;195(3):453–459.
Menghi F, et al. Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas. Sci Transl Med. 2022;14(652):eabo2572.
Ji G, et al. Germline and tumor BRCA1/2 pathogenic variants in Chinese triple-negative breast carcinomas. J Cancer Res Clin Oncol. 2021;147(10):2935–2944.
Glodzik D, et al. Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple-negative breast cancers. Nat Commun. 2020;11(1):3747.
Zhu X, et al. Stability and variability of molecular subtypes: comparative analysis of primary and metastatic triple-negative breast cancer. Cancer Biol Med. 2024;21(9).
Eras N, et al. Clinicopathological characteristics and BRCA1/BRCA2 pathogenic variants of patients with breast cancer. Pol J Pathol. 2024;75(1):1–7.
Muhammad N, et al. Contribution of constitutional BRCA1 promoter methylation to early-onset and familial breast cancer patients from Pakistan. Breast Cancer Res Treat. 2023;202(2):377–387.
Mahtani R, et al. Real-world study of regional differences in patient demographics, clinical characteristics, and BRCA1/2 mutation testing in patients with HER2-negative advanced breast cancer in the United States, Europe, and Israel. Adv Ther. 2023;40(1):190–207.
Feng C, et al. Relationship between homologous recombination deficiency and clinical features of breast cancer based on genomic scar score. Breast. 2023;69:68–77.
Guzmán-Arocho YD, et al. Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. Br J Cancer. 2022;126(2):302–309.
Boddicker NJ, et al. Risk of late-onset breast cancer in genetically predisposed women. J Clin Oncol. [S.l.: s.n.]. Available from: https://doi.org/10.
Chavarri-Guerra Y, et al. Breast cancer associated pathogenic variants among women 61 years and older with triple-negative breast cancer. J Geriatr Oncol. 2021;12(5):749–751.
